Pila Pharma AB
Research Pila Pharma AB (PILA) on Bullrun: market cap SEK 59.39M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPILA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 59.39M
- Financial periodFY2025
- RevenueSEK 1.13M
- Revenue growth45.4%
- Net income-SEK 17.00M
- Free cash flow-SEK 6.63M
Valuation Snapshot
latest market cap is SEK 59.39M.
About Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
Frequently asked questions
What is Pila Pharma AB's market cap?
Pila Pharma AB's market capitalization is SEK 59.39M.
What does Pila Pharma AB do?
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases;